We are happy to share another significant milestone with the growth of our client, Immunai, who recently signed a strategic cooperation agreement with AstraZeneca, one of the world’s leading pharmaceutical companies.
As part of the agreement, Immunai, which is at the forefront of application of artificial intelligence (AI) technology to biological systems, will help develop advanced tools for adjusting personal treatments based on immune system profiles. The first phase of the project is valued at 18 million dollars, with a potential for additional phases that will reach a total of 50 million dollars.
The collaboration with AstraZeneca will focus on identifying patients who are most likely to respond to certain treatments based on the interaction between their immune system and potential drugs, a move that could contribute to improving the accuracy of clinical trials and streamlining drug development processes.
Special thanks to the attorneys who worked on the transaction as well of members of the firm who advise Immunai on regulatory and technological matters: Daniel Green, Asaf Tenenbaum, Tamor Tavory, Roy Keidar and Yuli Rubinsky.
For more information about the collaboration, click here>>
